Furthermore, TVB2640 is currently under evaluation, alone or in combination with other drugs, in non-small cell lung carcinoma, HER2-positive advanced breast cancer, colorectal cancer, and high-grade relapsed astrocytoma as well as in subjects with non-alcoholic steatohepatitis (NCT03808558, NCT03179904, NCT02980029, NCT03032484, and NCT03938246). This evidence concerns the gene ERBB2 and metabolic dysfunction-associated steatohepatitis.